These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 29750418)

  • 1. Reply to the letter to the editor 'Androgen deprivation therapy and risk of rheumatoid arthritis in patients with localized prostate cancer' by Yang et al.
    Conteduca V; De Giorgi U; Lauletta G
    Ann Oncol; 2018 Aug; 29(8):1879-1880. PubMed ID: 29750418
    [No Abstract]   [Full Text] [Related]  

  • 2. 'Reply to the letter to the editor 'Androgen deprivation therapy and risk of rheumatoid arthritis in patients with localized prostate cancer' by Yang et al.' by V. Conteduca, U. De giorgi and G. Lauletta.
    Yang DD; Nguyen PL
    Ann Oncol; 2018 Sep; 29(9):2021-2022. PubMed ID: 30032198
    [No Abstract]   [Full Text] [Related]  

  • 3. Reply to Fabiana Gregucci and Alba Fiorentino's Letter to the Editor re: Liselotte M.S. Boevé, Maarten C.C.M. Hulshof, André N. Vis, et al. Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomized Clinical Trial: Data from the HORRAD Trial. Eur Urol 2019;75:410-8.
    Vis AN; Boevé LMS
    Eur Urol; 2019 May; 75(5):e131-e132. PubMed ID: 30616950
    [No Abstract]   [Full Text] [Related]  

  • 4. Reply to Bernard Tombal's letter to the editor re: Alessandro Sciarra, Per Anders Abrahamsson, Maurizio Brausi, et al. Intermittent androgen-deprivation therapy in prostate cancer: a critical review focused on phase 3 trials. Eur Urol 2013;64:722-30.
    Sciarra A
    Eur Urol; 2014 Apr; 65(4):e57. PubMed ID: 24388442
    [No Abstract]   [Full Text] [Related]  

  • 5. Reply to Herney Andrés García-Perdomo's Letter to the Editor re: Liselotte M.S. Boevé, Maarten C.C.M. Hulshof, André N. Vis, et al. Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial. Eur Urol. 2019;75:410-8. High-volume Disease Has a Different Standard of Care: Is Local Treatment Really Beneficial in Low-volume Metastatic Prostate Cancer?
    Boevé LMS; Vis AN
    Eur Urol; 2019 Apr; 75(4):e101-e102. PubMed ID: 30503181
    [No Abstract]   [Full Text] [Related]  

  • 6. Reply to Brandon A. Mahal, Anthony V. D'Amico, and Paul L. Nguyen's Letter to the Editor re: Neal D. Shore, Fred Saad, Michael S. Cookson, et al. Oral Relugolix for Androgen Deprivation Therapy in Advanced Prostate Cancer. N Engl J Med 2020;382:2187-96.
    Shore ND; Dearnaley D; Tombal B
    Eur Urol; 2020 Nov; 78(5):e196-e197. PubMed ID: 32838997
    [No Abstract]   [Full Text] [Related]  

  • 7. Reply to Ashwin Shinde, Richard Li, Arya Amini, and Scott Glaser's Letter to the Editor re: Liselotte M.S. Boevé, Maarten C.C.M. Hulshof, André N. Vis, et al. Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial. Eur Urol 2019;75:410-8: Future Steps for Definitive Therapy in Metastatic Prostate Cancer: Lessons from the HORRAD TrialUntil Randomised Controlled Trials Prove Different, Treat the Patient, Not His Imaging Results.
    Boevé LMS; Verhagen PCMS; Vis AN
    Eur Urol; 2019 Mar; 75(3):e71-e72. PubMed ID: 30471883
    [No Abstract]   [Full Text] [Related]  

  • 8. Reply to Yongfeng Lao, Yanan Wang, and Zhilong Dong's Letter to the Editor re: Amar U. Kishan, Xiaoyan Wang, Yilun Sun, et al. High-dose Radiotherapy or Androgen Deprivation Therapy (HEAT) as Treatment Intensification for Localized Prostate Cancer: An Individual Patient-data Network Meta-analysis from the MARCAP Consortium. Eur Urol. 2022;82:106-114.
    Kishan AU; Spratt DE
    Eur Urol; 2022 Sep; 82(3):e82-e83. PubMed ID: 35688665
    [No Abstract]   [Full Text] [Related]  

  • 9. Reply to the letter to the editor 'management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015' by Gillessen et al.
    Gillessen S; Fanti S; Omlin A;
    Ann Oncol; 2015 Nov; 26(11):2354-5. PubMed ID: 26347101
    [No Abstract]   [Full Text] [Related]  

  • 10. Reply to Mieke Van Hemelrijck, Hans Garmo, Jan Adolfsson, and Pär Stattin's Letter to the Editor re: Adi J. Klil-Drori, Hui Yin, Vicky Tagalakis, Armen Aprikian, Laurent Azoulay. Androgen Deprivation Therapy for Prostate Cancer and Risk of Venous Thromboembolism. Eur Urol 2016;70:56-61.
    Klil-Drori AJ; Azoulay L
    Eur Urol; 2017 Feb; 71(2):e63. PubMed ID: 27567205
    [No Abstract]   [Full Text] [Related]  

  • 11. Androgen deprivation therapy and risk of rheumatoid arthritis in patients with localized prostate cancer.
    Yang DD; Krasnova A; Nead KT; Choueiri TK; Hu JC; Hoffman KE; Yu JB; Spratt DE; Feng FY; Trinh QD; Nguyen PL
    Ann Oncol; 2018 Feb; 29(2):386-391. PubMed ID: 29267861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reply to Pirus Ghadjar and Thomas Wiegel's Letter to the Editor re: Abdenour Nabid, Nathalie Carrier, André-Guy Martin, et al. Duration of Androgen Deprivation Therapy in High-risk Prostate Cancer: A Randomized Phase III Trial. Eur Urol 2018;74:432-31.
    Nabid A; Souhami L
    Eur Urol; 2019 Mar; 75(3):e63. PubMed ID: 30773206
    [No Abstract]   [Full Text] [Related]  

  • 13. Anti-androgen treatment of prostatic carcinoma may be a risk factor for development of rheumatoid arthritis.
    Pope JE; Joneja M; Hong P
    J Rheumatol; 2002 Nov; 29(11):2459-62. PubMed ID: 12415609
    [No Abstract]   [Full Text] [Related]  

  • 14. Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer--Reply.
    D'Amico AV; Chen MH; Kantoff PW
    JAMA; 2016 Mar; 315(10):1055-6. PubMed ID: 26954420
    [No Abstract]   [Full Text] [Related]  

  • 15. Mortality and Androgen Deprivation Therapy as Salvage Treatment for Biochemical Recurrence after Primary Therapy for Clinically Localized Prostate Cancer.
    Fu AZ; Tsai HT; Haque R; Yood MU; Cassidy-Bushrow AE; Van Den Eeden SK; Keating NL; Smith MR; Zhou Y; Aaronson DS; Potosky AL
    J Urol; 2017 Jun; 197(6):1448-1454. PubMed ID: 28007467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reply to C. Mary Schooling, Grace Sembajwe and Ilir Agalliu's letter to the editor Re: Christina G. Jespersen, Mette Nørgaard, Michael Borre. Androgen-deprivation therapy in treatment of prostate cancer and risk of myocardial infarction and stroke: a nationwide Danish population-based cohort study.
    Jespersen CG; Nørgaard M; Borre M
    Eur Urol; 2013 Sep; 64(3):e61. PubMed ID: 23622775
    [No Abstract]   [Full Text] [Related]  

  • 17. Risk of diabetes among patients receiving primary androgen deprivation therapy for clinically localized prostate cancer.
    Tsai HT; Keating NL; Van Den Eeden SK; Haque R; Cassidy-Bushrow AE; Ulcickas Yood M; Smith MR; Potosky AL
    J Urol; 2015 Jun; 193(6):1956-62. PubMed ID: 25524243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reply from Authors re: Ronald C. Chen. Decisions Regarding Whether to Use Androgen Deprivation Therapy with Radiotherapy in Prostate Cancer: Is Cardiovascular Mortality the Most Relevant Outcome? Eur Urol 2016;69:211-2: Outcomes for Favorable and Unfavorable Intermediate Risk Prostate Cancer Patients Receiving Radiation Therapy With or Without Short-term Androgen Deprivation Therapy.
    Voog JC; Paulus R; Efstathiou JA
    Eur Urol; 2016 Feb; 69(2):212-3. PubMed ID: 26443430
    [No Abstract]   [Full Text] [Related]  

  • 19. Androgen Deprivation Therapy for Prostate Cancer and the Risk of Rheumatoid Arthritis: A Population-Based Cohort Study.
    Klil-Drori AJ; Santella C; Tascilar K; Yin H; Aprikian A; Azoulay L
    Drug Saf; 2019 Aug; 42(8):1005-1011. PubMed ID: 31240687
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reply to letter to editor regarding: LHRH analog therapy is associated with worse metabolic side effects than bilateral orchiectomy in prostate cancer.
    Cognette MC; da Silva AV; Machado RD; Faria EF
    World J Urol; 2018 Apr; 36(4):683-684. PubMed ID: 29470648
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.